MedPath

Humacyte's Symvess Receives FDA Approval for Vascular Repair, Stock Soars

• Humacyte's shares experienced a 38% surge following the FDA's full approval of Symvess for adult patients, indicating strong market confidence. • Symvess is approved as a vascular conduit for extremity arterial injuries when urgent blood flow restoration is needed to prevent limb loss. • The approval is specific to cases where vein grafts are not feasible, offering a new option for complex vascular repairs in trauma cases. • Symvess has been utilized in various traumatic injuries, including those from car accidents, gunshot wounds, and industrial incidents.

Humacyte has announced that the Food and Drug Administration (FDA) has granted full approval to Symvess, a novel vascular conduit, for use in adult patients. This approval, disclosed on Thursday, led to a significant surge in Humacyte's stock, with shares jumping 38% in premarket trading.

Indication and Use

Symvess is indicated for use as a vascular conduit in cases of extremity arterial injury where urgent restoration of blood flow is necessary to avert imminent limb loss. The approval is specifically for situations where a vein graft, typically used for vascular repair, is not a viable option. This provides a crucial alternative for surgeons facing challenging reconstructive scenarios.

Clinical Application

According to Humacyte, Symvess has been employed in the repair of various traumatic injuries, including those resulting from car accidents, gunshot wounds, blast wounds, and industrial accidents. The availability of Symvess offers a potentially life-saving option in these critical situations, where rapid and effective vascular repair is paramount.
The stock is up 22% on the year, trading around $4.81.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Humacyte's Bioengineered Vessel SYMVESS Receives FDA Approval for Extremity Vascular Trauma

The FDA has approved SYMVESS, Humacyte's acellular tissue-engineered vessel, for treating extremity arterial injuries in adults when urgent revascularization is needed.
SYMVESS offers a readily available alternative to autologous vein grafts, reducing surgical time and avoiding additional incisions in already-injured patients.

Sagimet Biosciences' Denifanstat Shows Promise in MASH Treatment, Stock Surges

Sagimet Biosciences' Denifanstat receives FDA Breakthrough Therapy designation for metabolic dysfunction-associated steatohepatitis (MASH), accelerating its development and review process.
Phase 2b FASCINATE-2 trial demonstrates statistically significant improvements in liver health metrics, resolving MASH and improving fibrosis, key indicators for the condition.

Roche to Acquire Poseida Therapeutics; Merck, AstraZeneca, and Novartis Report Pipeline Success

Roche will acquire Poseida Therapeutics for $1.0 billion, expanding its CAR-T therapy portfolio, targeting hematological malignancies, solid tumors, and autoimmune diseases.
Merck's Winrevair phase III study met its primary endpoint, showing a statistically significant reduction in morbidity or mortality events in advanced pulmonary arterial hypertension.

Biofrontera's Ameluz Demonstrates High Efficacy in Phase III sBCC Trial

Biofrontera's Ameluz-PDT therapy met the primary endpoint, showing 65.5% success in complete clearance of superficial basal cell carcinoma (sBCC) lesions, compared to 4.8% with placebo.
The Phase III trial demonstrated that 75.9% of participants treated with Ameluz-PDT achieved complete histological clearance, versus 19% in the placebo group.

Summit Therapeutics' Lung Cancer Drug Ivonescimab Receives FDA Fast Track Designation

Summit Therapeutics' stock experienced a surge following the FDA's Fast Track designation for its lung cancer drug, ivonescimab, indicating accelerated review potential.
The company has completed enrollment for a Phase 3 trial of ivonescimab, involving patients across North America, Europe, and China, marking its first global study.

Viridian Therapeutics' Veligrotug Achieves Positive Phase III Results in Thyroid Eye Disease

Viridian Therapeutics' veligrotug met all primary and secondary endpoints in the Phase III THRIVE trial for active thyroid eye disease (TED).
The trial demonstrated statistically significant improvements in signs and symptoms of TED after 15 weeks of veligrotug treatment compared to placebo.

Strides Pharma Receives USFDA Approval for Generic Theophylline Extended-Release Tablets

Strides Pharma's subsidiary secures USFDA approval for generic Theophylline extended-release tablets, used for chronic asthma and lung diseases.
The approved drug, a generic version of Theo-Dur, addresses symptoms like wheezing and shortness of breath by relaxing bronchial muscles.

Vaxcyte's Pneumococcal Vaccine Candidate Outperforms Pfizer's Prevnar 20 in Early Trial

Vaxcyte's shares surged by 36% following the release of promising data on its pneumococcal vaccine candidate, VAX-24, which aims to rival Pfizer's Prevnar franchise.
In a preliminary trial involving 1,015 healthy adults aged 50 and older, Vaxcyte's VAX-24 demonstrated superior performance compared to Pfizer's Prevnar 20.

MAIA Biotechnology's Shares Surge Following FDA Approval of Telomerase Inhibitor

MAIA Biotechnology's stock increased by 14% following the FDA's approval of imetelstat, validating telomere targeting as a viable therapeutic approach.
The FDA approved Geron Corp's imetelstat for treating rare blood cancers originating in bone marrow, specifically low- to intermediate-risk myelodysplastic syndromes.

Iterum Therapeutics' Sulopenem Application Review Progresses, FDA Action Date on Track

Iterum Therapeutics completed a late-cycle meeting with the FDA regarding its sulopenem etzadroxil/probenecid application for uncomplicated urinary tract infections.
The FDA has indicated that an Advisory Committee meeting is not currently necessary, maintaining the target action date of July 25.

Reference News

[1]
Humacyte Shares Surge 38% on FDA Approval of Symvess | Morningstar
morningstar.com · Dec 20, 2024

Humacyte shares surged 38% in premarket trading after FDA full approval of Symvess for extremity arterial injury, avoidi...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy